Table 2.
Open in new tab

Nonserious AESIs

AESIsTotal no. of eventsPatients with AESI, n (%)
Any AESI1,079399 (60.7)
Evidence of liver toxicity249137 (20.9)
New onset or worsened hypertension199160 (24.4)
Thyroid dysfunction10890 (13.7)
Cardiac dysfunction1816 (2.4)
Any other event resulting in pazopanib dose modification or discontinuation505233 (35.5)
AESIsTotal no. of eventsPatients with AESI, n (%)
Any AESI1,079399 (60.7)
Evidence of liver toxicity249137 (20.9)
New onset or worsened hypertension199160 (24.4)
Thyroid dysfunction10890 (13.7)
Cardiac dysfunction1816 (2.4)
Any other event resulting in pazopanib dose modification or discontinuation505233 (35.5)

All treated patients (n = 657).

Abbreviations: AESIs, adverse events of special interest.

Table 2.
Open in new tab

Nonserious AESIs

AESIsTotal no. of eventsPatients with AESI, n (%)
Any AESI1,079399 (60.7)
Evidence of liver toxicity249137 (20.9)
New onset or worsened hypertension199160 (24.4)
Thyroid dysfunction10890 (13.7)
Cardiac dysfunction1816 (2.4)
Any other event resulting in pazopanib dose modification or discontinuation505233 (35.5)
AESIsTotal no. of eventsPatients with AESI, n (%)
Any AESI1,079399 (60.7)
Evidence of liver toxicity249137 (20.9)
New onset or worsened hypertension199160 (24.4)
Thyroid dysfunction10890 (13.7)
Cardiac dysfunction1816 (2.4)
Any other event resulting in pazopanib dose modification or discontinuation505233 (35.5)

All treated patients (n = 657).

Abbreviations: AESIs, adverse events of special interest.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close